Merit Medical Launches Embosphere® and HepaSphere Microspheres in Japan

I am pleased to announce that Nippon Kayaku (authorized distributor for Merit Medical Systems, Inc.) has received distribution and marketing authorization in Japan for Embosphere Microspheres and HepaSphere Microspheres.
The Japan Ministry of Health, Labour and Welfare held the “10th Investigative Commission about Expedited Introduction of Medical Devices, Which Are Strongly Needed in Medical Treatment” and it recommended the introduction of Embosphere and HepaSphere Microspheres to the Japan market. The recommendation was fulfilled by approval of both products in June 2013.
Embosphere Microspheres, the most clinically studied round embolic, provide consistent and predictable results for effective embolization in the treatment of uterine fibroids, hypervascular tumors, and arteriovenous malformations. Used worldwide in over 250,000 procedures since 2002, Embosphere Microspheres are the gold standard in uterine fibroid embolization, with Interventional Radiologists choosing Embosphere Microspheres in 73% of cases according to the FIBROID registry published in Obstetrics and Gynecology.
HepaSphere Microspheres are biocompatible, hydrophilic, nonresorbable, and conformable microspheres designed for controlled, targeted embolization. HepaSphere Microspheres also rapidly absorb aqueous solutions such as contrast media or saline. HepaSphere Microspheres enable physicians to optimize outcomes by more precisely matching the sphere size to the size of the targeted vasculature. In Japan, HepaSphere Microspheres are indicated for use in embolization of blood vessels for therapeutic or preoperative purposes in the following procedures:

 

  • Embolization of hepatocellular carcinoma
  • Embolization of metastases to the liver
Please visit our product pages for more information.
Noah Wong
Product Manager, Merit Medical

You Have Options For Treating Your Uterine Fibroids

Did you know that there are minimally-invasive treatment options available to treat uterine fibroids and the common symptoms associated with them: heavy bleeding, pelvic pain, and frequent urination?
In 2008, Uterine Fibroid Embolization (UFE) was recognized by the American College of Obstetricians and Gynecologists (ACOG) as an alternative to hysterectomy in the management of uterine fibroids.
      If you are not a good candidate for hysterectomy,
      If you want to avoid surgery for your fibroids,
      If you want to keep your uterus,
ASK ABOUT UFE!
UFE is a proven, effective option for treating uterine fibroids. To learn more about your options, go to www.ask4ufe.com.

Merit Medical Announces the Latest in Inflation Device Technology– the New basixTOUCH™

Merit Medical’s 35 ATM basixTOUCH Inflation Device is now available in the U.S., Europe, and many other countries around the world. The basixTOUCH is the latest innovation in inflation from Merit, and offers 35 ATM pressure capability as well as 30 mL of syringe volume to make it easier to accommodate a wide array of interventional balloons.

We surveyed hundreds of physicians and techs, and found a strong desire for a device that was easy on the hands, quick to set up, easy to inflate, and fast to deflate. From this feedback, Merit has designed a device with one-handed prep, an easy-to-turn quick-release handle.

basixtouch

The basixTOUCH expands your capacity with the innovation, quality, and reliability that Merit customers have enjoyed for over 25 years. To learn more about this new product and other products supporting interventional and diagnostic procedures, please contact your local Merit Sales Representative or visit us at www.merit.com.

Guido Sandulli
Director of Marketing, Interventional Cardiology

First Commercial Cases with STAR System in Europe